Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children

Article Article scientifique Article Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children eng 2012 author Iskedjian Michael author Belli Dominique Charles 26369 author Farah Bechara author Navarro Vincent author Detzel Patrick 26911 378-393 10.3111/13696998.2011.650521 22171935 1369-6998 A pharmacoeconomic analysis was undertaken to determine costs, consequences, and cost-effectiveness of a partially hydrolyzed 100% whey-based infant formula, NAN-HA®, manufactured by Nestlé S.A, Switzerland (PHF-W), branded under BEBA HA® in Switzerland, in the prevention of atopic dermatitis (AD) in 'at risk' Swiss children when compared to standard cow's milk formula (SF). Child, Preschool Cost-Benefit Analysis Dermatitis, Atopic/economics/prevention & control Dietary Proteins Economics, Pharmaceutical Health Resources/economics/utilization Humans Infant Infant Formula/chemistry/economics Milk Hypersensitivity Milk Proteins Models, Economic Outcome Assessment (Health Care) Sensitivity and Specificity Switzerland Dewey 618 58 Département de pédiatrie, gynécologie et obstétrique 223 false 147 Gastroentérologie et transplantation (pédiatrie) 181 Journal of medical economics 15 2 394074e6-527c-46c9-aaa3-1d6b78463c59 Article (Published version) Restricted 378-393[1].pdf 4147966 application/pdf restrictedAccess Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children	Journal of medical economics			2012	628	0

Archive ouverte UNIGE

Detzel, Patrick